Auxilium Pharmaceuticals, Inc. To Announce Fourth Quarter And Full Year 2013 Results On February 28, 2014 - NEWS10 ABC: Albany, New York News, Weather, Sports

Auxilium Pharmaceuticals, Inc. To Announce Fourth Quarter And Full Year 2013 Results On February 28, 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Auxilium Pharmaceuticals, Inc.

-Company to Host Conference Call That Day at 9 a.m. ET-

CHESTERBROOK, Pa., Feb. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the fourth quarter and full year 2013 on Friday, February 28, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 9 a.m. ET to discuss results and highlights of the fourth quarter and full year 2013 and to provide financial guidance for 2014. The presentation slides to be used during the call will be available on the "Investors" section of the Company's website under the "Presentations" tab beginning at 9 a.m. ET on Friday, February 28, 2014.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

A live webcast of the conference call, presentation and question and answer session will be available on the "Investors" section of the Company's website under the "Events" tab. To access the live webcast, please log on to Auxilium's site approximately 15 minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for 90 days after the event.  

Conference call details:


Date:

Friday, February 28, 2014

Time:

9:00 a.m. ET

Dial-in (U.S.):

877-546-5018

Dial-in (International):

857-244-7550

Web cast:

http://www.auxilium.com

Passcode:

AUXILIUM

To access an audio replay of the call:


Access number (U.S.):

888-286-8010

Access number (International):

617-801-6888

Replay Passcode #:

27946131

About Auxilium
Auxilium Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences. With a broad range of first- and second-line products across multiple indications, Auxilium is an emerging leader in the men's healthcare area and has strategically expanded its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The Company now has a broad portfolio of 12 approved products. Among other products in the U.S., Auxilium markets Edex® (alprostadil for injection), an injectable treatment for erectile dysfunction, Osbon ErecAid®, the leading device for aiding erectile dysfunction, STENDRA™ (avanafil), an oral erectile dysfunction therapy, Testim® (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL® (testosterone pellets) a long-acting implantable testosterone replacement therapy, XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease and XIAFLEX for the treatment of Dupuytren's contracture. The Company also has programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite. Auxilium's mission is to improve the lives of patients throughout the world by successfully identifying, developing and commercializing innovative specialty biopharmaceutical products. To learn more, please visit www.Auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to: the Company's intention to announce fourth quarter and full year 2013 earnings and the timing of such announcement; and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2012 and in other public filings with the SEC, including, without limitation, as such Form 10-K was updated in Item 8.01 of the Current Report on Form 8-K filed on April 29, 2013 and Auxilium's Quarterly Reports for 2013. While Auxilium may elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so. Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov. There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

Auxilium Contacts: 




Keri P. Mattox / SVP, IR &

Nichol L. Ochsner / Senior Director, IR &

Corporate Communications

Corporate Communications

Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc. 

(484) 321-5900

(484) 321-5900

kmattox@auxilium.com

nochsner@auxilium.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
     
NEWS10 ABC
341 Northern Boulevard
Albany, NY 12204
+(518) 436-4822
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WTEN. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.